These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38789451)

  • 21. Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil.
    Valentim J; Sartori AM; de Soárez PC; Amaku M; Azevedo RS; Novaes HM
    Vaccine; 2008 Nov; 26(49):6281-91. PubMed ID: 18674582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Cost-Effectiveness of Universal Varicella Vaccination in Italy: A Model-Based Assessment of Vaccination Strategies.
    Azzari C; Baldo V; Giuffrida S; Gani R; O'Brien E; Alimenti C; Daniels VJ; Wolfson LJ
    Clinicoecon Outcomes Res; 2020; 12():273-283. PubMed ID: 32606844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial.
    Prymula R; Bergsaker MR; Esposito S; Gothefors L; Man S; Snegova N; Štefkovičova M; Usonis V; Wysocki J; Douha M; Vassilev V; Nicholson O; Innis BL; Willems P
    Lancet; 2014 Apr; 383(9925):1313-1324. PubMed ID: 24485548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined measles-mumps-rubella-varicella vaccine and febrile convulsions: the risk considered in the broad context.
    Casabona G; Berton O; Singh T; Knuf M; Bonanni P
    Expert Rev Vaccines; 2023; 22(1):764-776. PubMed ID: 37642012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Varicella vaccination in England and Wales: cost-utility analysis.
    Brisson M; Edmunds WJ
    Arch Dis Child; 2003 Oct; 88(10):862-9. PubMed ID: 14500303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
    MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of 2-dose routine measles, mumps, rubella, and varicella vaccination in France on the epidemiology of varicella and zoster using a dynamic model with an empirical contact matrix.
    Ouwens MJ; Littlewood KJ; Sauboin C; Téhard B; Denis F; Boëlle PY; Alain S
    Clin Ther; 2015 Apr; 37(4):816-829.e10. PubMed ID: 25726457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting?
    Bilcke J; van Hoek AJ; Beutels P
    Hum Vaccin Immunother; 2013 Apr; 9(4):812-22. PubMed ID: 23321955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model.
    Wolfson LJ; Daniels VJ; Pillsbury M; Kurugöl Z; Yardimci C; Kyle J; Dinleyici EC
    PLoS One; 2019; 14(8):e0220921. PubMed ID: 31408505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccines for measles, mumps, rubella, and varicella in children.
    Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD004407. PubMed ID: 32309885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of a vaccination programme in children vaccinated with ProQuad, and ProQuad-specific effectiveness against varicella in the Veneto region of Italy.
    Giaquinto C; Gabutti G; Baldo V; Villa M; Tramontan L; Raccanello N; Russo F; Poma C; Scamarcia A; Cantarutti L; Lundin R; Perinetti E; Cornen X; Thomas S; Ballandras C; Souverain A; Hartwig S
    BMC Infect Dis; 2018 Mar; 18(1):103. PubMed ID: 29506477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modelling Hospitalisation Ratios for Febrile Convulsions and Severe Varicella Under Combined Measles, Mumps, Rubella, and Varicella (MMRV-Priorix-Tetra™) Compared to Separate MMR + V Vaccination.
    Bauchau V; Van Holle L; Cohen C
    Drug Saf; 2015 Nov; 38(11):1095-102. PubMed ID: 26251259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Public health and economic benefits of seasonal influenza vaccination in risk groups in France, Italy, Spain and the UK: state of play and perspectives.
    de Fougerolles TR; Baïssas T; Perquier G; Vitoux O; Crépey P; Bartelt-Hofer J; Bricout H; Petitjean A
    BMC Public Health; 2024 May; 24(1):1222. PubMed ID: 38702667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and economic impact of universal varicella vaccination in Norway: A modeling study.
    Pawaskar M; Burgess C; Pillsbury M; Wisløff T; Flem E
    PLoS One; 2021; 16(7):e0254080. PubMed ID: 34237090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preparing to introduce the varicella vaccine into the Italian immunisation programme: varicella-related hospitalisations in Tuscany, 2004-2012.
    Boccalini S; Bonanni P; Bechini A
    Euro Surveill; 2016 Jun; 21(24):. PubMed ID: 27336188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of a routine varicella vaccination program for US children.
    Lieu TA; Cochi SL; Black SB; Halloran ME; Shinefield HR; Holmes SJ; Wharton M; Washington AE
    JAMA; 1994 Feb; 271(5):375-81. PubMed ID: 8283587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia.
    Macartney K; Gidding HF; Trinh L; Wang H; Dey A; Hull B; Orr K; McRae J; Richmond P; Gold M; Crawford N; Kynaston JA; McIntyre P; Wood N;
    JAMA Pediatr; 2017 Oct; 171(10):992-998. PubMed ID: 28806450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cost-effectiveness of routine childhood varicella vaccination in Germany.
    Banz K; Wagenpfeil S; Neiss A; Goertz A; Staginnus U; Vollmar J; Wutzler P
    Vaccine; 2003 Mar; 21(11-12):1256-67. PubMed ID: 12559807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Post-marketing surveillance of adverse events following measles, mumps, rubella and varicella (MMRV) vaccine: retrospecive study in apulia region (ITALY), 2009-2017.
    Stefanizzi P; De Nitto S; Patano F; Bianchi FP; Ferorelli D; Stella P; Ancona D; Bavaro V; Tafuri S
    Hum Vaccin Immunother; 2020 Aug; 16(8):1875-1883. PubMed ID: 32040350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany.
    Wutzler P; Neiss A; Banz K; Goertz A; Bisanz H
    Med Microbiol Immunol; 2002 Oct; 191(2):89-96. PubMed ID: 12410347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.